Based on the Generation Bio Co stock forecast from 1 analysts, the average analyst target price for Generation Bio Co is USD 10.00 over the next 12 months. Generation Bio Co’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Generation Bio Co is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Generation Bio Co’s stock price was USD 0.37. Generation Bio Co’s stock price has changed by -0.37% over the past week, -22.08% over the past month and -89.89% over the last year.
No recent analyst target price found for Generation Bio Co
No recent average analyst rating found for Generation Bio Co
Company Overview Generation Bio Co
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle, or ctLNP platform. ctLNP delivery system is designed to address the limitations of existing technologies and comprises three elements. First, LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen. Second, identify and refine a small format targeting ligand against a receptor uniquely expressed on the target cell to achieve highly potent and selective delivery to specific tissues and cell types of interest. Finally, bioconjugated linkers that facilitate modular attachment of the targeting ligands to the core stealth LNP; and novel immune-quiet DNA (iqDNA) enable long-lasting high levels of gene expression from non-integrating episomes and avoid innate immune sensors that have long prevented DNA from use in non-viral systems. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read Less
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle, or ctLNP platform. ctLNP delivery system is designed to address the limitations of existing technologies and comprises ...Read More
Frequently Asked Questions About Generation Bio Co (GBIO) Stock
Based on ratings from 1 analysts Generation Bio Co's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on GBIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GBIO is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
GBIO stock's Price/Earning ratio is -99,999.99.
Our analysis grades GBIO stock's Price / Earning ratio at A+. This means that GBIO stock's Price/Earning ratio is above 1.000000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this GBIO may be undervalued for its sector.
The last closing price of GBIO's stock was USD 0.37.
The most recent market capitalization for GBIO is USD 0.03B.
Based on targets from 1 analysts, the average taret price for GBIO is projected at USD 10.00 over the next 12 months.
This means that GBIO's stock price may go up by +2,573.80% over the next 12 months.
We can't find any ETFs which contains Generation Bio Co's stock.
As per our most recent records Generation Bio Co has 115 Employees.
Generation Bio Co's registered address is 301 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Generation Bio Co's website at https://generationbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Frequently Asked Questions About Generation Bio Co (GBIO) Stock
Based on ratings from 1 analysts Generation Bio Co's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on GBIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for GBIO is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
GBIO stock's Price/Earning ratio is -99,999.99.
Our analysis grades GBIO stock's Price / Earning ratio at A+. This means that GBIO stock's Price/Earning ratio is above 1.000000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this GBIO may be undervalued for its sector.
The last closing price of GBIO's stock was USD 0.37.
The most recent market capitalization for GBIO is USD 0.03B.
Based on targets from 1 analysts, the average taret price for GBIO is projected at USD 10.00 over the next 12 months.
This means that GBIO's stock price may go up by +2,573.80% over the next 12 months.
We can't find any ETFs which contains Generation Bio Co's stock.
As per our most recent records Generation Bio Co has 115 Employees.
Generation Bio Co's registered address is 301 Binney Street, Cambridge, MA, United States, 02142.
You can get more information about it from Generation Bio Co's website at https://generationbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
